Liraglutide for Management of Obesity in People Living With HIV on Dolutegravir-based Antiretroviral Therapy: a Single-arm Acceptability Study in South Africa
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Proportion of participants who screen and enroll among those approached
研究概览
简要总结
The goal of this single-arm, open label pilot study is to evaluate liraglutide at the recommended dosage administered subcutaneously + lifestyle counselling for the management of people living with HIV (PLWH) with obesity defined by a BMI ≥30 kg/m2 who are on dolutegravir-based ART.
Following individual informed consent, all participants will undergo a series of basic cardiometabolic labs. They will then be initiated on liraglutide 0.6 mg administered subcutaneously, and this dose will be gradually increased over a period of 4 weeks to a dose of 3.0 mg daily. Alongside drug administration, participants will receive lifestyle counselling regarding diet and physical activity. Following completion of a 12-week "on treatment" period, liraglutide will be stopped and participants will be followed for an additional 12-weeks off treatment. Body weight, cardiometabolic risk parameters, and a suite of patient-reported outcomes regarding diet, physical activity, sleep, and quality of life will be assessed periodically over the course of the study.
详细描述
South Africa has the largest population of PLWH globally, with a prevalence of 17% in adults or 7.2 million PLWH. The rapid scale-up of ART programs has resulted in >6 million PLWH on treatment, significant gains in life expectancy, and a large population of aging PLWH. With increasing life expectancy, obesity and type 2 diabetes have become growing threats for PLWH in South Africa and globally. One recent study found that 63% of PLWH are overweight or obese, and 6% have diabetes in this setting.
This elevated risk of obesity in PLWH in South Africa is likely due to a confluence of both general considerations and HIV-specific factors. First, South Africa has experienced an accelerated background epidemic of metabolic disease in the general population with a prevalence of overweight and obesity that is nearly equal to that of high-income countries. Additionally, the International Diabetes Federation estimates that approximately 15.5 million adults are living with diabetes in the African Region, and projects it to grow to 41 million by 2045. As part of this background epidemic of metabolic disease, South Africa is also experiencing a nutrition transition, with widespread availability of processed and refined foods as well as sugar-sweetened beverages.
Regarding HIV-specific issues, in 2019 the first-line ART regimen for the South African national HIV treatment program transitioned to TLD. TLD is generally very safe and well-tolerated and has a high barrier to HIV resistance but this transition to this regimen has been associated with risk of excess weight gain at the population level. Both clinical trials and observational studies conducted in South Africa have shown substantial increases in body weight in those who are initiating this ART regimen newly and among those who are suppressed and switched, especially women. Given this, there is a growing risk of obesity in PLWH in this context and a need for management strategies to address this increasingly prevalent comorbidity.
Preventing the metabolic complications of HIV in South Africa and worldwide requires urgent solutions. To date, obesity management and diabetes prevention have largely consisted of behavioural interventions such as the Diabetes Prevention Program and related lifestyle modification efforts, focused on improving diet and increasing physical activity. However, in the past several years, novel anti-obesity pharmacologic agents such as the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown enormous promise for obesity management and diabetes prevention in people who are HIV-negative (8-10). However, this drug class has a very limited evidence base in PLWH and relatively scant data from sub-Saharan African populations.
Currently, liraglutide is the only GLP-1 RA approved for obesity management in South Africa and this protocol proposes to use the drug for its labelled indication of "weight loss in addition to diet and exercise in adults aged 18 and above who have: (1) a BMI of 30 or greater (obese) or (2) a BMI of greater than 27 and less than 30 (overweight) and weight related health problems (such as diabetes, high blood pressure, hypercholesterolemia, or obstructive sleep apnoea).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able to give written informed consent to participate in the study
- •Able to comply with all study procedures, including daily subcutaneous injections
- •Adults ≥18 years old
- •PLWH on dolutegravir-based ART for ≥6 months
- •Documented HIV-1 viral load in the past 6 months confirming the participant is virologically suppressed
- •BMI ≥30 kg/m2
- •Desiring weight loss
- •Willing to undertake lifestyle change
- •Not on any weight loss agent for the duration of the study
排除标准
- •Self-reported history of diabetes
- •Current use of medications for diabetes
- •Known contraindications to liraglutide, such as hypersensitivity to a component of the drug
- •Current pregnancy or desire to become pregnant
- •History of pancreatitis
- •History of thyroid disease
- •History of harmful use of alcohol
- •Clinically unstable in the opinion of the investigator
研究组 & 干预措施
Lirgalutide
Following individual informed consent, all participants will undergo a series of basic cardiometabolic labs. They will then be initiated on liraglutide 0.6 mg administered subcutaneously, and this dose will be gradually increased over a period of 4 weeks to a dose of 3.0mg daily. Alongside drug administration, participants will receive lifestyle counselling regarding diet and physical activity. Following completion of a 12-week "on treatment" period, liraglutide will be stopped and participants will be followed for an additional 12-weeks off treatment. Body weight, cardiometabolic risk parameters, and a suite of patient-reported outcomes regarding diet, physical activity, sleep, and quality of life will be assessed periodically over the course of the study.
干预措施: Liraglutide (Drug)
结局指标
主要结局
Proportion of participants who screen and enroll among those approached
时间窗: Measured at screening
This will be expressed in terms of the proportion of participants who attend screening and enrolment visits among the total number who are approached regarding interest in study participation.
Rate of adherence to treatment over 12 weeks
时间窗: Measured at Visit 4 at 12 weeks
The investigators will assess volume remaining in the injector pens and provide a percentage of doses per participant that remained unused at the end of the 12-week period on treatment.
Embedded qualitative interviews regarding the acceptability of liraglutide for obesity management
时间窗: Measured at End of Study at 24 weeks
This will be open-ended responses to a brief exit interview about acceptability and feasibility.
Study retention rate at 12 weeks
时间窗: Measured at Visit 4 at 12 weeks
This will be expressed as a proportion of participants who remain in the study after the 12 week "on treatment" period among those enrolled.
Study retention rate at 24 weeks
时间窗: Measured at End of Study at 24 weeks
This will be expressed as a proportion of participants who remain in the study after the full 24 weeks of study procedures are completed among those enrolled.
Time to reach study enrollment target
时间窗: Measured at enrollment
次要结局
- Change in body weight over 24 weeks (12 weeks on + 12 weeks off treatment)(Measured at End of Study at 24 weeks)
- Change in HbA1c following 12 weeks on treatment(Measured at Visit 4 at 12 weeks)
- Change in depressive symptoms over 24 weeks (12 weeks on + 12 weeks off treatment)(Measured at End of Study at 24 weeks)
- Incidence of treatment-emergent adverse events as defined in this protocol(From the initiation of treatment until the date of a treatment-emergent adverse event, assessed up to 24 weeks.)
- Change in HbA1c over 24 weeks (12 weeks on + 12 weeks off treatment)(Measured at End of Study at 24 weeks)
- Change in fasting plasma glucose following 12 weeks on treatment(Measured at Visit 4 at 12 weeks)
- Change in fasting plasma glucose over 24 weeks (12 weeks on + 12 weeks off treatment)(Measured at End of Study at 24 weeks)
- Change in depressive symptoms following 12 weeks on treatment(Measured at Visit 4 at 12 weeks)
- Change in dietary habits following 12 weeks on treatment(Measured at Visit 4 at 12 weeks)
- Incidence of serious adverse events (SAEs), as defined in this protocol(From the initiation of treatment until the date of a serious adverse event, assessed up to 24 weeks.)
- Change in body weight following 12 weeks on treatment(Measured at Visit 4 at 12 weeks)
- Change in dietary habits over 24 weeks (12 weeks on + 12 weeks off treatment)(Measured at End of Study at 24 weeks)
- Change in physical activity level following 12 weeks on treatment(Measured at Visit 4 at 12 weeks)
- Change in physical activity level over 24 weeks (12 weeks on + 12 weeks off treatment)(Measured at End of Study at 24 weeks)
研究者
Jennifer M. Manne-Goehler, MD, SCD
Assistant Professor of Medicine
Brigham and Women's Hospital